NewcelX (NCEL) Other Non-Current Liabilities (2023 - 2024)
NewcelX (NCEL) posted quarterly Other Non-Current Liabilities of $5.1 million for Q4 2024, up 405.09% year-over-year from $1.0 million in Q1 2024, and up 405.09% quarter-over-quarter from $1.0 million in Q4 2023.
NewcelX (NCEL) Other Non-Current Liabilities (2023 - 2024) Analysis & Trends
NewcelX (NCEL) has reported Other Non-Current Liabilities for 2 consecutive years, with $5.1 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Other Non-Current Liabilities rose 405.09% year-over-year to $5.1 million; the TTM figure through Dec 2024 stood at $5.1 million (up 405.09% YoY), while the FY2024 annual figure was $5.1 million, up 405.09% from the prior year.
- Other Non-Current Liabilities advanced to $5.1 million in Q4 2024 per NCEL's latest filing, from $1.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $5.1 million in Q4 2024 and bottomed at $50000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NewcelX | 12.54 Mn | 10.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.06 Mn |
| Dec 31, 2023 | 1.00 Mn |
| Jun 30, 2023 | 50,000.00 |